RESUMO
The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.
Assuntos
Antirretrovirais/farmacologia , Infecções por HIV/tratamento farmacológico , Política de Saúde , Países em Desenvolvimento , Farmacorresistência Viral , Saúde Global , Inquéritos Epidemiológicos , Humanos , Organização Mundial da SaúdeRESUMO
The case of a previously healthy man with endocarditis due to the group C streptococcus, complicated by myocardial abscess and fatal cardiac tamponade, is presented. Group C streptococcus is an unusual cause of endocarditis which tends to produce extensive valve destruction. Early surgery should be considered in patients with endocarditis caused by this organism.
Assuntos
Tamponamento Cardíaco/etiologia , Endocardite Bacteriana/complicações , Infecções Estreptocócicas/complicações , Adulto , Endocardite Bacteriana/patologia , Humanos , Masculino , Infecções Estreptocócicas/patologiaRESUMO
The in-vitro activity of cefpirome, cefotaxime, ticarcillin, piperacillin, and three aminoglycosides was compared by the broth dilution method against 248 consecutive clinical isolates of Pseudomonas aeruginosa and 35 aminoglycoside-resistant isolates of the Enterobacteriaceae. Cefpirome was more active against Ps. aeruginosa than cefotaxime and gentamicin, and as active as piperacillin, ticarcillin, tobramycin and amikacin. Ps. aeruginosa isolates resistant to a given aminoglycoside were significantly more resistant to cefpirome than isolates susceptible to that aminoglycoside. Other beta-lactam antibiotics were also less active against aminoglycoside-resistant strains of Ps. aeruginosa. Cefpirome was more potent than cefotaxime and the penicillins against aminoglycoside-resistant Enterobacteriaceae.